55
Participants
Start Date
December 13, 2023
Primary Completion Date
January 3, 2025
Study Completion Date
January 13, 2025
KAN-101
Dose KAN-101 Intravenous (IV) Infusion
Placebo
Placebo Intravenous (IV) Infusion
Studiengesellschaft BSF Unternehmergesellschaft, Halle
Clinical Research Services Turku, Turku
Unlimited Medical Research Group, Hialeah Gardens
Homestead Associates in Research Inc., Miami
Tays Research Services, Tampere
Alliance for Multispecialty Research, LLC, Wichita
Ochsner Clinic Foundation, New Orleans
Peak Gastroenterology Associates, Colorado Springs
Rabin Medical Center, Petah Tikva
Sheba Medical Center, Ramat Gan
Soroka Medical Center, Beersheba
Shaare Zedek Medical Center, Jerusalem
Beth Israel Deaconess Medical Center, Boston
McMaster University, Hamilton
LHSC, London
Centre Intégré de Santé et de Services Sociaux-Chaudière Appalaches - Hôtel-Dieu de Lévis, Lévis
Hopital Du Sacre-Coeur De Montreal, Montreal
Diex Recherche Quebec Inc., Québec
CRST Helsinki Oy, Helsinki
Connolly Hospital, Dublin
Our Lady of Lourdes Hospital, Drogheda
Midland Regional Hospital Mullingar, Mullingar
Albert Schweitzer Ziekenhuis, locatie Dordwijk, Dordrecht
Gastromed Sp. z o. o., Torun
Melita Medical, Wroclaw
WIP Warsaw IBD Point Profesor Kierkuś, Warsaw
MZ Badania Slowik Zymla Spolka Jawna, Knurów
Centrum Medyczne Med-Gastr Sp. z o.o., Lodz
Collaborators (1)
Pfizer
INDUSTRY
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
INDUSTRY